Verapamil for Neuroprotection in Stroke
Key facts
- Where
- Atlantic City, Langhorne, and Upland, United StatesSee the 3 sites
- Phase
- Phase 1/2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Where in United States
- AtlantiCare Regional Medical CenterAtlantic City, United StatesTaking people
- St Mary Medical CenterLanghorne, United StatesNot yet recruiting
- Crozer-Chester Medical CenterUpland, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Global Neurosciences Institute
- Trial code
- NCT03347786
- Record updated
- 17 January 2025
- Original description
The purpose of this research study is to test an experimental procedure called intra-arterial delivery of verapamil in patients diagnosed with acute ischemic stroke. This study investigates the safety of intra-arterial delivery of verapamil, a drug used to treat vasospasm (spasm of a blood vessel), and how it affects recovery from stroke. Recruitment is limited to patients that have received mechanical thrombectomy as standard of care.Read full original descriptionShow less
Intraarterial Verapamil for Neuroprotection in Ischemic Stroke
The purpose of this research study is to test an experimental procedure called intra-arterial delivery of verapamil in patients diagnosed with acute ischemic stroke. This study investigates the safety of intra-arterial delivery of verapamil, a drug used to treat vasospasm (spasm of a blood vessel), and how it affects recovery from stroke. Recruitment is limited to patients that have received mechanical thrombectomy as standard of care.
Inclusion: Written informed consent; 18 years of age and over; Acute onset focal neurologic deficit consistent with acute ischemic stroke, or computed tomographic scan consistent with acute cerebral ischemia; Candidate for mechanical thrombectomy procedure; Onset of symptoms less than 8 hours; Measurable neurologic deficit (NIHSS ≥4); Willingness to follow up with rehabilitation therapy; Anticipated life expectancy of at least 3 months.
Exclusion: Previous functional disability (modified Rankin > 1); Hepatic and/or renal insufficiency (LFT's>3× upper limit of normal; CrCl < 30ml/min); History of intolerance to verapamil; Severe stroke (NIHSS>22); Thrombocytopenia (platelet count <75,000/mm3); Pregnancy or suspected pregnancy (pregnancy test will be done on women of child-bearing potential); Stuporous or comatose; Unlikely to be available for 90 day follow-up.